Russell Petty MBChB, PhD, MRCPE, FRCP

Professor Russell Petty is a graduate of the University of Dundee School of Medicine, and he completed his initial general medical training in Dundee, Newcastle, and Hobart, then specialist and academic training in Medical Oncology in Aberdeen and Auckland. In 2007, he was appointed as a Clinical Senior Lecturer in Medical Oncology at the University of Aberdeen and promoted to Professor of Medical Oncology in 2014. In September 2015, he was appointed as Professor of Medical Oncology at the University of Dundee and an honorary consultant in Medical Oncology at Ninewells Hospital, NHS Tayside.

His main research interests are in clinical and translational research in gastro-oesophageal cancers. He was the chief investigator of the recently completed COG trial, which was the first Phase III randomised controlled trial of second-line therapy in oesophageal cancer and led the translational arm TRANSCO, which identified a predictive biomarker for a gefitinib-responsive subgroup of tumours. He is a current member of the trial management groups for several UK national clinical trials in gastroesophageal cancer, including PLATFORM and GO-2 and the translational research lead for TRANS-GO2 and TRANSCOG2.

Professor Petty is the current speciality adviser in Medical Oncology to the Chief Medical Officer in Scotland. He acts as a clinical expert for SMC and NICE and recently contributed to the Scottish Parliament Health and Sport Committee enquiry into access to new medicines in Scotland and the reform of the SMC process for evaluation of new medicines, which included the development of the patient and clinician engagement (PACE) process. He is a current member of the NCRN UGI cancers clinical study group and the EORTC gastric cancer task force, and a member of the Editorial Board of BMC Cancer.